Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830424 | 0.89 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL735657 | 0.89 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7122592 | 0.89 | POLB (0.80) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7469413 | 0.82 | PKM (0.72) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4526586 | 0.82 | POLB (0.69) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6805741 | 0.81 | ALDH1A1 (0.81) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1988224 | 0.81 | ALDH1A1 (0.81) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14470279 | 0.81 | ALDH1A1 (0.75) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20458879 | 0.80 | POLB (0.67) | POLBPKMALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20198535 | 0.80 | POLB (0.67) | POLBPKMALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173132-B2 | Certain substituted 1-aryl-3-piperazine-1′-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATRICS CORPORATION (US) | 2003-12-25 | — | — | US | disclosed |
| EP-0966462-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| EP-0925286-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2003-01-02 | — | — | EP | disclosed |
| US-6391880-B1 | ANTICHOLESTEROL AGENTS | ZENECA LIMITED (GB) | 2002-05-21 | — | — | US | disclosed |
| US-6306857-B1 | INHIBITION OF ABNORMALLY PHOSPHORYLATED | MOLECULAR GERIATRICS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | MOLECULAR GERIATARICS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6214994-B1 | TREATMENT OF NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS, AND PREVENTING OR DECREASING PRODUCTION OF PHOSPHORYLATED PAIRED HELICAL FILAMENT (PHF) EPITOPES ASSOCIATED WITH ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION | 2001-04-10 | — | — | US | disclosed |
| US-6093718-A | AN OXIDO-SQUALENE CYCLASE INHIBITOR, ANTICHOLESTEROL AGENT FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND LOWERING CHOLESTEROL LEVELS IN BLOOD PLASMA; TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2000-07-25 | — | — | US | disclosed |
| US-6075026-A | Certain substituted 1-aryl-3-piperazin-1'-yl propanones | MOLECULAR GERIATRICS, CORP. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0966462-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ZENECA LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| EP-0925286-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998035959-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ZENECA LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
| WO-1998006705-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ZENECA LIMITED (GB) | 1998-02-19 | — | — | WO | disclosed |
| US-5693804-A | USEFUL IN TREATING NEOPLASTIC DISEASES, BACTERIAL OR FUNGAL INFECTIONS AND ALZHEIMER'S DISEASE | MOLECULAR GERIATRICS CORPORATION (US) | 1997-12-02 | — | — | US | disclosed |
| US-5658909-A | INHIBITION OF ABNORMALLY PHOSPHORYLATED PAIRED HELICAL FILAMENT EPITOPE FORMATION | MOLECULAR GERIATRICS CORPORATION (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1996015792-A9 | METHODS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE USING SUBSTITUTED 1-ARYL-3-PIPERAZIN-1'-YL PROPANONES | — | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236403-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | POLB 3613/4885PKM 720/4885ALDH1A1 3122/4885 |
| US-20010025105-A1 | Certain substituted 1-aryl-3-piperazine-1'-yl propanones | PSEN1, PSEN2, PRNP | POLB 3613/4885PKM 720/4885ALDH1A1 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.